Hematology focuses on diseases of the blood, bone marrow, and lymphatic system. Learn about the diagnosis and treatment of anemia, leukemia, and lymphoma.
Send us all your questions or requests, and our expert team will assist you.
Multiple Myeloma is a complex hematologic malignancy that arises from plasma cells, a specific type of white blood cell found in the bone marrow. Under normal physiological conditions, plasma cells are a critical component of the adaptive immune system. They develop from B lymphocytes (B cells) and are responsible for producing antibodies (immunoglobulins) that help the body fight infections by recognizing and neutralizing pathogens like bacteria and viruses. In Multiple Myeloma, a genetic mutation occurs in a single plasma cell, causing it to become cancerous. This abnormal cell, now called a myeloma cell, begins to multiply uncontrollably. Unlike normal plasma cells that produce helpful antibodies, these cancerous cells produce an abnormal, non functional protein known as monoclonal protein (M protein) or paraprotein. As these malignant cells accumulate, they crowd out healthy blood cells in the bone marrow and release chemicals that damage bones and organs. At Liv Hospital, we approach Multiple Myeloma not just as a bone marrow disease, but as a systemic condition that requires a deep understanding of immunology and cellular biology for effective management.
From Defense to Disease
To understand myeloma, one must understand the environment in which it develops. The bone marrow is the spongy tissue inside the bones where blood cells are made.
Normal Function
In a healthy individual, B cells mature into plasma cells when they encounter an infection. These plasma cells then reside in the bone marrow and produce diverse antibodies (polyclonal) to target specific invaders. This diversity is essential for broad immune protection.
Clonal Expansion
In myeloma, the process of replication becomes disordered. Instead of a diverse population of plasma cells, the marrow becomes overrun by a single clone of identical cancer cells. These cells produce a single type of antibody (monoclonal) which offers no immune protection and accumulates in the blood and urine, leading to the clinical features of the disease.
Multiple Myeloma rarely appears suddenly; it typically evolves from asymptomatic precursor states. Understanding this spectrum is vital for monitoring and early intervention.
Monoclonal Gammopathy of Undetermined Significance (MGUS)
This is a common, benign condition, especially in older adults. In MGUS, there is a small amount of M protein in the blood (<3 g/dL) and a low percentage of plasma cells in the marrow (<10%), with no damage to the body. Most people with MGUS never develop cancer, but all myeloma cases start as MGUS.
Smoldering Multiple Myeloma (SMM)
This is an intermediate stage between MGUS and active myeloma. The M protein levels or plasma cell counts are higher than in MGUS, but there are still no symptoms or organ damage. These patients have a much higher risk of progressing to active myeloma and require close surveillance.
Active Multiple Myeloma
This stage is defined by the presence of myeloma cells and evidence of organ damage, specifically known as “myeloma defining events.” This transition marks the point where treatment becomes necessary to prevent severe complications.
How Myeloma Affects the Body
The accumulation of myeloma cells and M proteins disrupts normal bodily functions through several mechanisms.
Bone Destruction
Myeloma cells produce cytokines (signals) that stimulate osteoclasts (cells that break down bone) and inhibit osteoblasts (cells that build bone). This imbalance leads to lytic lesions (holes in the bones), osteoporosis, and fractures.
Marrow Infiltration
As myeloma cells fill the bone marrow space, they leave no room for the production of red blood cells, white blood cells, and platelets. This leads to anemia, immune suppression, and bleeding issues.
Protein Deposition
The excess M protein can thicken the blood (hyperviscosity) or clog the filtering tubules of the kidneys, leading to renal failure.
Types of M Proteins
Myeloma is often classified by the type of defective immunoglobulin produced.
IgG and IgA Myeloma
These are the most common types. IgG myeloma accounts for about 60 percent of cases, while IgA accounts for about 20 percent.
Light Chain Myeloma
In about 20 percent of cases, the myeloma cells do not produce the whole antibody but only the “light chain” part. These small proteins are easily filtered by the kidneys and can cause significant renal damage. This is often referred to as Bence Jones myeloma.
Non Secretory Myeloma
In rare cases, the myeloma cells do not release any M protein into the blood. This makes diagnosis more challenging, relying heavily on bone marrow biopsies and advanced imaging.
Who is Affected
Multiple Myeloma is the second most common blood cancer.
Age Factors
It is primarily a disease of older adults. The median age at diagnosis is around 69 years. It is rare in people under 45.
Racial Disparities
There is a significant genetic component related to ancestry. Multiple Myeloma is more than twice as common in African Americans compared to Caucasian populations.
Gender
Men are slightly more likely to develop the disease than women, though the reasons for this hormonal or genetic predisposition remain under investigation.
Cytogenetic Abnormalities
The behavior of myeloma is largely dictated by the specific genetic mutations within the cancer cells.
Standard Risk
Some patients have genetic markers that suggest a slower growing disease that responds well to standard treatments (e.g., hyperdiploidy).
High Risk
Other patients have specific chromosomal changes, such as the deletion of chromosome 17p or translocation t(4;14). These markers indicate a more aggressive disease that may require more intensive therapy. Identifying these markers at Liv Hospital is a standard part of our initial assessment to tailor the treatment plan.
Send us all your questions or requests, and our expert team will assist you.
No, it is a blood cancer that starts in the bone marrow. While it damages the bones, the cancer cells are plasma cells, not bone cells.
MGUS is a benign condition with no symptoms or organ damage, while Myeloma is a cancer that causes damage to bones, kidneys, or blood counts.
While it is generally considered treatable rather than curable, modern therapies allow many patients to live for many years with the disease in deep remission.
Plasma cells are white blood cells that produce antibodies to help the body fight infections. Myeloma is a cancer of these specific cells.
No, small amounts of M protein can be found in MGUS, which is not cancer. However, it indicates a need for medical monitoring.
Your Comparison List (you must select at least 2 packages)
